Tango Therapeutics, Inc.
$26.39
▲
1.93%
2026-04-21 09:51:01
www.tangotx.com
NGM: TNGX
Explore Tango Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.8 B
Current Price
$26.39
52W High / Low
$26.81 / $1.03
Stock P/E
—
Book Value
$2.55
Dividend Yield
—
ROCE
-29.52%
ROE
-37.23%
Face Value
—
EPS
$-0.84
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
137
Beta
1.31
Debt / Equity
9.7
Current Ratio
16.32
Quick Ratio
16.32
Forward P/E
-12.52
Price / Sales
45.63
Enterprise Value
$2.54 B
EV / EBITDA
-23.27
EV / Revenue
40.67
Rating
Strong Buy
Target Price
$21.4
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Kodiak Sciences Inc. | $46.44 | — | $2.87 B | — | -76.6% | -1.49% | $47.41 / $2.34 | $2.55 |
| 2. | XORTX Therapeutics Inc. | $2.25 | — | $4.16 M | — | -156.2% | -98% | $9.85 / $2.42 | $0.3 |
| 3. | Cardio Diagnostics Holdings, Inc. | $1.97 | — | $5.95 M | — | -90.54% | -78.62% | $17.4 / $0.97 | $3.82 |
| 4. | Enlivex Ltd. | $0.88 | — | $207.92 M | — | -0.65% | 1.26% | $2.1 / $0.66 | $8.15 |
| 5. | Ensysce Biosciences, Inc. | $0.48 | — | $4.49 M | — | -355% | -3.25% | $4.85 / $0.31 | $0.7 |
| 6. | Pulmatrix, Inc. | $1.34 | — | $4.91 M | — | -135.67% | -80.93% | $9.37 / $1.16 | $1.04 |
| 7. | Azitra, Inc. | $0.21 | — | $3.48 M | — | -277.12% | -2.31% | $2.66 / $0.1 | $0.35 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 53.81 M | 3.18 M | 5.39 M | 4.12 M |
| Operating Profit | -41.86 M | 14.07 M | -40.97 M | -42.53 M | -40.91 M |
| Net Profit | -38.75 M | 15.88 M | -38.85 M | -39.88 M | -37.67 M |
| EPS in Rs | -0.27 | 0.11 | -0.27 | -0.28 | -0.26 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 62.38 M | 42.07 M | 36.53 M | 24.86 M |
| Operating Profit | -111.29 M | -145.59 M | -114.17 M | -111.07 M |
| Net Profit | -101.59 M | -130.3 M | -101.74 M | -108.18 M |
| EPS in Rs | -0.71 | -0.91 | -0.71 | -0.76 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 398.69 M | 316.49 M | 402.57 M | 436.47 M |
| Total Liabilities | 52.51 M | 116.97 M | 149.46 M | 186.99 M |
| Equity | 346.18 M | 199.52 M | 253.11 M | 249.48 M |
| Current Assets | 353.76 M | 266.34 M | 346.54 M | 375.27 M |
| Current Liabilities | 21.68 M | 38.17 M | 45.94 M | 55.55 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -138.89 M | -131.5 M | -117.98 M | -109.08 M |
| Investing CF | -40.87 M | 86.13 M | 41.43 M | 26.4 M |
| Financing CF | 222.5 M | 47.66 M | 82.41 M | 1.61 M |
| Free CF | -139.93 M | -132.25 M | -119.51 M | -116.77 M |
| Capex | -1.05 M | -0.75 M | -1.53 M | -7.69 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 15.17% | 46.93% | — | — |
| Earnings Growth % | -28.07% | 5.95% | — | — |
| Profit Margin % | -309.73% | -278.54% | -435.14% | — |
| Operating Margin % | -346.09% | -312.57% | -446.79% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -340.15% | -305.96% | -440.32% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.